
Sirnaomics is committed to developing innovative biopharmaceutical drugs leveraging our novel delivery platforms in a wide variety of disease indications, including oncology, fibrotic diseases and conditions, viral diseases and cardiometabolic diseases. We are focused on developing new delivery platforms for RNA therapeutics to maintain and broaden the scope of our product pipeline, and to overcome the limitations of conventional RNA delivery tools. Once our targets have been selected based on clear scientific rationale, we apply a proprietary algorithm based on our understanding of the biochemical mechanisms involved in RNA interference to identify promising candidate RNAi trigger sequences against the selected target gene and employ high throughput processes to design, screen and rigorously test future pipeline products.
We have built a pipeline through in-house development of both our product candidates and our RNAi and mRNA delivery platforms. We believe the success of RNA-based therapeutics relies on three pillars: (1) the selection of the right targets; (2) the application of suitable delivery platforms; and (3) the selection of appropriate therapeutic indications. We have developed in-house and own the global rights to STP705 and STP707, our lead product candidates, which demonstrates our capabilities in designing novel RNA therapeutics based on our innovative and adaptable delivery platforms and developing them into drugs to address unmet medical needs. Our proprietary delivery platforms include our PNP delivery platform, useful for local or systemic administration of RNAi therapeutics to targets beyond liver hepatocyte cells, our GalNAc RNAi delivery platforms for system administration of RNAi therapeutics to the liver, and our PLNP delivery platform for administration of mRNA vaccines and therapeutics. We exclusively in-licensed core patents covering our PNP delivery platform at an early stage and have conducted research and development in-house to enhance our PNP delivery platform and adapt it for formulating novel RNA therapeutics to treat a range of therapeutic indications. We have developed in-house and own the global rights to innovative GalNAc RNAi delivery platforms. Our PNP and GalNAc RNAi delivery platforms fuel our expanding pipeline of early-stage product candidates. Our subsidiary RNAimmune develops mRNA-based vaccines and therapeutics.
We have a comprehensive portfolio of patents to protect our drug candidates and technologies. We own 9 issued patents in China, 9 issued patents in the U.S., 2 issued patents in Europe (validated in 11 and 8 countries, respective). And We also have 119 pending patent applications, including 19 Chinese patent applications, 43 U.S. patent applications (including 32 U.S. provisional patent applications), 8 patent applications under the Patent Cooperation Treaty, 6 patent applications in Europe, and 43 patent applications in other jurisdictions. Our patents and patent applications span methods of delivering RNAi triggers and mRNA to cells, compositions of matter and devices used in our RNAi and mRNA delivery platforms, siRNA or RNAi trigger compositions, manufacturing processes, usage, and indications.
We are led by our visionary management team with deep experience and capabilities in discovering, developing, and commercializing RNA therapeutics. Management team and scientific advisory board average more than 20 years of pharma research and development experience at the world’s leading pharmaceutical companies and research institutions in China and the U.S. Thus we are able to attract top talents and build strong teams across markets.

research and development in-house to enhance our PNP delivery platform and adapt it for formulating novel RNA therapeutics to treat a range of therapeutic indications. We have developed in-house and own the global rights to innovative GalNAc RNAi delivery platforms. Our PNP and GalNAc RNAi delivery platforms fuel our expanding pipeline of early-stage product candidates. Our subsidiary RNAimmune develops mRNA-based vaccines and therapeutics.
We have a comprehensive portfolio of patents to protect our drug candidates and technologies. As of the Latest Practicable Date, we owned (i) 9 issued patents in China, (ii) 9 issued patents in the U.S., (iii) 2 issued patents in Europe (validated in 11 and 8 countries, respective), and (iv) 116 pending patent applications, including 19 Chinese patent applications, 39 U.S. patent applications (including 28 U.S. provisional patent applications), 9 patent applications under the Patent Cooperation Treaty, 6 patent applications in Europe and 43 patent applications in other jurisdictions. Our patents and patent applications span methods of delivering RNAi triggers and mRNA to cells, compositions of matter and devices used in our RNAi and mRNA delivery platforms, siRNA or RNAi trigger compositions, manufacturing processes, usage and indications.
We are led by our visionary management team with deep experience and capabilities in discovering, developing and commercializing RNA therapeutics. In addition, our management team and scientific advisory board have on average more than 20 years of pharma research and development experience at the world’s leading pharmaceutical companies and research institutions in China and the U.S. Thus we are able to attract top talents and build strong teams across markets.
Drug Delivery Systems
We believe our highly innovative RNA delivery platforms set us in a class by ourselves. The primary challenge and the key to success in developing RNA therapeutics is the delivery platform used to protect the RNA from degradation in the blood and deliver the RNA into a cell where it acts. Our proprietary PNP and novel GalNAc delivery platforms confer advantages over conventional delivery platforms.
Our PNP delivery platform allows delivery of both siRNA and mRNA to diseased cells via local or systemic administration, providing distinct advantages in low toxicity, easy manufacturing and the capability to reach many targeted organs and certain cell types. The success of our Phase IIa oncology study validates both the effectiveness of our PNP delivery platform and the therapeutic targets for isSCC, positioning us for accelerated development of other pipeline products using the same PNP delivery platform. Our proprietary GalNAc RNAi delivery platforms, GalAhead™ and PDoV-GalNAc, enable specific delivery to liver hepatocytes with enhanced endosome escape properties and dual siRNA target design, resulting in high potency.